| 摘要 |
The invention relates to NEP inhibitors for treating cardiovascular disorders wherein R<1 >is C1-C6alkyl, C1-C6alkoxyC1-C3alkyl or C1-C6alkoxyC1-C6alkoxyC1-C3alkyl; R<2 >is hydrogen or C1-C6alkyl; L is an aromatic heterocyclic ring, optionally substituted with C1-C6alkyl or halo; R<3 >is C1-C6alkyl optionally substituted by halo, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group, or R<3 >is phenyl or aromatic heterocyclyl each of which may be independently substituted by one or more alkyl, halo, haloalkyl, alkoxy, haloalkoxy, alkylthio, haloalkylthio or nitrile group; R<4 >and R<5 >are either both hydrogen, or one of R<4 >and R<5 >is hydrogen and the other is a biolabile ester-forming group that in the body of a patient is replaced by hydrogen; p is 0, 1 or 2; and q is 1 or 2. |
